Reading the tape
NASDAQ: PMVP
PMV Pharmaceuticals, Inc.
Healthcare · Biotechnology
Market Cap
$75.99M
52w High
$1.88
52w Low
$0.81
P/E
-0.98
Volume
894.00
Outstanding Shares
53.33M
Price vs Fundamentals
Why The Stock Is Moving
Mixed / unclearLow confidence
Note: The most recent financial data is over 3 months old. Metrics shown may not reflect the latest reporting period.
1Y Price: 49.11%FCF (TTM): -41.72%
What changed
The stock rose 49.11% over the last year. Free cash flow declined 41.72% over the trailing twelve months.
What the market seems to be pricing
The stock has moved higher against modestly weakening underlying metrics. The operating data does not yet tell a clear story — the move may reflect sentiment, sector rotation, or macro factors rather than company-specific earnings power.
What would invalidate this read
A decisive shift in revenue or cash flow over the next period would be the clearest signal to resolve the ambiguity.
Company profile
PMV Pharmaceuticals, Inc., a precision oncology company, engages in the discovery and development of small molecule and tumor-agnostic therapies for p53 mutations in cancer.
CEODavid H. Mack
SectorHealthcare
IndustryBiotechnology
Employees47
IPO dateSep 25, 2020
Valuation
Forward P/E—
EV/EBITDA-0.33
Enterprise value$28.53M
Stock splits
No stock splits recorded for this ticker.
Profitability & growth
Revenue growth—
Gross margin0%
Operating margin0%
ROE-74.24%▼122.67%vs FY2024
Analyst consensus
RatingBuy
Target price$18.00▲1163.16%
4
Buy
0
Hold
0
Sell
Analyst ratings tend to be lagging indicators. Use as one signal among many.
Earnings
Full quarter-by-quarter history of actuals vs estimates. Switch into compare mode to inspect one metric year-over-year.
Next report
May 8, 2026
Q2 FY26 · EPS est -$0.40 · Revenue est —
View